Literature DB >> 27658187

c-Met inhibition enhances chemosensitivity of human ovarian cancer cells.

Jing Wang1, Jian-Xin Cheng1.   

Abstract

In clinical practice, human ovarian cancer shows considerable resistance to chemotherapy. This study aimed to investigate the role of c-Met in the chemoresistance of ovarian cancer. Ovarian cancer cell line SKOV3 and OVCAR-3 were pretreated with c-Met inhibitor INCB28060, and then treated with paclitaxel. Cell survival, cell cycle and apoptosis were analyzed by MTT assay, flow cytometry analysis and TUNEL assay, respectively. The activation of c-Met signalling was detected by western blot analysis. INCB28060 inhibited the survival of SKOV3 and OVCAR-3 cells and enhanced the chemosensitivity of SKOV3 and OVCAR-3 cells to paclitaxel. INCB28060 inhibited c-Met signalling, caused mitochondrial membrane depolarization and DNA repair, and induced the apoptosis of SKOV3 and OVCAR-3 cells. c-Met plays an important role in mediating the chemoresistance of ovarian cancer. The combination of c-Met inhibitor and chemotherapy is a promising strategy to human ovarian cancer.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  INCB28060; OVCAR-3; SKOV3; c-Met; chemotherapy; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 27658187     DOI: 10.1111/1440-1681.12672

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

1.  Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.

Authors:  Xixi Zhao; Jingkun Qu; Yuxin Hui; Hong Zhang; Yuchen Sun; Xu Liu; Xiaoyao Zhao; Zitong Zhao; Qian Yang; Feidi Wang; Shuqun Zhang
Journal:  Oncotarget       Date:  2017-05-24

2.  Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.

Authors:  Nehad M Ayoub; Kamal M Al-Shami; Mohammad A Alqudah; Nizar M Mhaidat
Journal:  Onco Targets Ther       Date:  2017-10-05       Impact factor: 4.147

Review 3.  Recurrence of ovarian squamous cell carcinoma with MET gene copy number variation: a case report and review of literature.

Authors:  Xuhui Dong; Lei Yuan; Liangqing Yao
Journal:  J Ovarian Res       Date:  2020-05-31       Impact factor: 4.234

4.  MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel.

Authors:  Megumi Yanokura; Kouji Banno; Daisuke Aoki
Journal:  Int J Oncol       Date:  2020-09-23       Impact factor: 5.650

Review 5.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.

Authors:  Yazhuo Zhang; Mengfang Xia; Ke Jin; Shufei Wang; Hang Wei; Chunmei Fan; Yingfen Wu; Xiaoling Li; Xiayu Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

6.  Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.

Authors:  Razan Sheta; Magdalena Bachvarova; Marie Plante; Marie-Claude Renaud; Alexandra Sebastianelli; Jean Gregoire; Jamilet Miranda Navarro; Ricardo Bringas Perez; Jean-Yves Masson; Dimcho Bachvarov
Journal:  J Transl Med       Date:  2020-11-19       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.